	US 11,932,676 B2
	Recombinant klotho proteins and compositions and methods involving same
Joseph F. Tarsio, Manilus, NY (US); Dinesh Raturi, Eastville, CA (US); and James R. Plante, Las Vegas, NV (US)
Assigned to KLOTHO THERAPEUTICS, INC., Las Vegas, NV (US)
Appl. No. 16/462,864
Filed by KLOTHO THERAPEUTICS, INC., Las Vegas, NV (US)
PCT Filed Nov. 22, 2017, PCT No. PCT/US2017/063149 § 371(c)(1), (2) Date May 21, 2019, PCT Pub. No. WO2018/098375, PCT Pub. Date May 31, 2018.
Claims priority of provisional application 62/425,237, filed on Nov. 22, 2016.
Claims priority of provisional application 62/456,318, filed on Feb. 8, 2017.
Prior Publication US 2020/0181224 A1, Jun. 11, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 38/47 (2006.01); A61K 47/68 (2017.01); A61P 13/12 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C12N 9/24 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/705 (2013.01) [A61K 38/1709 (2013.01); A61K 38/47 (2013.01); A61K 47/6811 (2017.08); A61K 47/6889 (2017.08); A61P 13/12 (2018.01); C07K 14/47 (2013.01); C12N 9/2402 (2013.01); A61K 38/00 (2013.01); C07K 2317/52 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01); C07K 2319/50 (2013.01)]

20 Claims

1. A method of treating and/or preventing acute kidney injury or chronic kidney disease in a mammalian subject, the method comprising:

administering to the mammalian subject a pharmaceutical composition comprising:

a pharmaceutically acceptable carrier or excipient; and

an effective amount of a recombinant fusion protein comprising:

a Klotho protein sequence having 100% amino acid sequence identity to SEQ ID NO: 109; and

an immunoglobulin Fc domain having at least 99% amino acid sequence identity to SEQ ID NO: 74; and

optionally, a linker disposed between the Klotho protein sequence and the immunoglobulin Fc domain.